Though ALK and ROS1 fusion proteins existed in multiple tumor types, ALK and ROS1 kinases inhibitors are only approved for ALK or ROS1‐positive NSCLC before July 14, 2022. Here, ROS1 is linked to non-small cell lung carcinoma.